Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HNF4A | P41235 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15510700 | 0.92 | KDM4E (0.40) | KDM4ELMNAPIN1CYP1A2MAPK1 | |
| SCHEMBL3383809 | 0.91 | KDM4E (0.46) | KDM4ELMNAPIN1CYP1A2MAPK1 | |
| SCHEMBL949150 | 0.85 | CCNC (0.41) | KDM4ELMNA | |
| SCHEMBL954343 | 0.85 | BCAT2 (0.47) | KDM4ELMNACYP1A2MAPK1CYP2C19 | |
| SCHEMBL27508282 | 0.85 | TPMT (0.43) | KDM4ELMNAPIN1MAPK1TP53 | |
| SCHEMBL952491 | 0.84 | MKNK1 (0.50) | CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL16109091 | 0.84 | KDM4E (0.36) | KDM4ELMNAPIN1CYP1A2MAPK1 | |
| SCHEMBL28954225 | 0.84 | ALDH1A1 (0.40) | KDM4ELMNAALDH1A1PTPN1PRKAB2 | |
| SCHEMBL1776218 | 0.84 | CA12 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15758825 | 0.84 | CA12 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1658755-A | Herbicidal aromatic carboxylic acids and safeners | BAYER CROPSCIENCE GMBH (DE) | 2005-08-24 | — | — | CN | claimed |
| EP-1515606-A2 | COMBINATIONS OF HERBICIDAL AROMATIC CARBOXYLIC ACIDS AND SAFENERS | Bayer CropScience GmbH (DE) | 2005-03-23 | — | — | EP | claimed |
| WO-2003103394-A2 | COMBINATIONS OF HERBICIDAL AROMATIC CARBOXYLIC ACIDS AND SAFENERS | BAYER CROPSCIENCE GMBH (DE) | 2003-12-18 | — | — | WO | claimed |
| US-20030232725-A1 | Combinations of herbicidal aromatic carboxylic acids and safeners | BAYER CROPSCIENCE AG (DE) | 2003-12-18 | — | — | US | claimed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4180424-A1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230094305-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-30 | — | — | US | disclosed |
| EP-1175419-B1 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | WEXLER RUTH R (US) | 2003-03-13 | — | — | US | disclosed |
| US-6399644-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2002-06-04 | — | — | US | disclosed |
| US-5082949-A | Plant growth regulators, protective agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-21 | — | — | US | disclosed |
| EP-0352581-A2 | Ethylene diaminmonoamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-31 | — | — | EP | disclosed |
| US-4891057-A | Phenylpyrazolecarboxylic acid derivatives, their preparation, and their use as plant-growth regulators and safeners | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-01-02 | — | — | US | disclosed |
| US-4891057-A | Phenylpyrazolecarboxylic acid derivatives, their preparation, and their use as plant-growth regulators and safeners | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | F12, F11, TFPI | KDM4E 1129/4885LMNA 1793/4885PIN1 3336/4885 |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KDM4E 954/4885LMNA 998/4885PIN1 1755/4885 |
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KDM4E 1055/4885LMNA 1195/4885PIN1 1937/4885 |
| US-20230094305-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KDM4E 1688/4885LMNA 824/4885PIN1 2753/4885 |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KDM4E 954/4885LMNA 998/4885PIN1 1755/4885 |
| US-20030232725-A1 | Combinations of herbicidal aromatic carboxylic acids and safeners | DDT, CYP2W1, AADAC | KDM4E 3880/4885LMNA 4612/4885PIN1 561/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KDM4E 1688/4885LMNA 824/4885PIN1 2753/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KDM4E 954/4885LMNA 998/4885PIN1 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.